The coordinating institution Heidelberg University Hospital combines partners with experience in innovative cervical cancer early detection and public health. The department of Applied Tumor Biology discovers and evaluates novel means for screening and treatment of HPV-associated diseases. Based on new candidates they design, coordinate, and realize diagnostic and therapeutic clinical studies. Scientists from the Applied Tumor Biology had a strong impact in establishing the diagnostic role of p16 as a specific biomarker for transforming HPV infections. They have ongoing clinical trials on novel drugs for treatment of HPV-associated neoplasia. On the long run these may be implemented in cervical cancer screening approaches in sub-Saharan Africa. Both Heidelberg partners, the department of Applied Tumor Biology as well as the Institute of Public Health, have ongoing successful collaborations with Kenya and Ethiopia on HIV and cervical cancer.
Our study team combines cervical cancer experts from the fields of cancer biology, epidemiology, biostatistics, clinical trials, public health, clinical oncology, and gynecology. All participants have prior experience with studies in Africa. This unique group will allow addressing the different proposed objectives with the necessary multidisciplinary approach and on a high level of scientific quality.
Heidelberg University Hospital with its 44 specialized clinical departments is one of the leading medical centers in Europe. Every year, hundreds of thousands of patients from all over Germany and many other countries come here to make use of our modern treatment facilities. The highest standards of medical care are guaranteed by our world-renowned professors, distinguished physicians and committed nursing staff. Heidelberg University Hospital is constantly developing new methods of diagnosis and treatment at the forefront of biomedical science for the benefit of all patients.
The department of Applied Tumor Biology investigates the molecular mechanisms of tumor development and progression. In patients’ diagnostics, analyses are performed for tumor classification and cancer early detection. In research, novel diagnostic markers and antigens, which are relevant for immunotherapy, are identified. Based on these markers, clinical studies are planned and performed. There is a close collaboration with different clinical and theoretical institutions as well as the National Center for Tumor Diseases (NCT), the German Cancer Research Center (DKFZ) and the European Molecular Biological Laboratory (EMBL), and several industrial partners. Our teaching activity comprises lectures, seminars, and colloquia in the field of applied tumor biology.